BamSEC and AlphaSense Join Forces
Learn More

Fulcrum Therapeutics Inc. – Material Contracts

NASDAQ: FULC    
Share price (9/23/26): $3.81    
Market cap (9/23/26): $291 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.15
from S-4 4 pages Certain Information Has Been Excluded From This Agreement (Indicated by “[***]”) Because Slate Medicines, Inc. Has Determined Such Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to License Agreement
12/34/56
EX-10.14
from S-4 65 pages Certain Information Has Been Excluded From This Agreement (Indicated by “[***]”) Because Slate Medicines, Inc. Has Determined Such Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement Between Dartsbio Pharmaceuticals Ltd. and Slate Medicines, Inc. February 16, 2026
12/34/56
EX-10.13
from S-4 36 pages Office Lease
12/34/56
EX-10.12
from S-4 13 pages Dated February 17, 2026 Slate Medicines, Inc. Slate Medicines Uk Limited Forbion Ventures Fund VII Coöperatief U.A and Fordd Ventures VII B.V. Share Exchange Agreement
12/34/56
EX-10.11
from S-4 14 pages Employment Agreement
12/34/56
EX-10.10
from S-4 19 pages Employment Agreement
12/34/56
EX-10.9
from S-4 20 pages Employment Agreement
12/34/56
EX-10.8
from S-4 37 pages Slate Medicines, Inc. 2024 Equity Incentive Plan Board of Directors Stockholders Adopted September 10, 2024 Approved September 10, 2024 Amended February 17, 2026 Amended February 17, 2026 Termination Date: September 09, 2034
12/34/56
EX-10.5
from 8-K 21 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 34 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 7 pages Form of Lock-Up Agreement
12/34/56
EX-10.2
from 8-K 19 pages Company Support Agreement
12/34/56
EX-10.1
from 8-K 18 pages Parent Support Agreement
12/34/56
EX-10.4
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 10-Q 10 pages Material contract
12/34/56
EX-10.20
from 10-K 13 pages Fulcrum Therapeutics, Inc. Executive Employment Agreement This Executive Employment Agreement (The “Agreement”) Is Revised as of December 22, 2025 (The “Effective Date”) by and Between Fulcrum Therapeutics, Inc. (The “Company”) and Curt Oltmans (The “Executive”) (The Company and the Executive Each a “Party” and Together the “Parties”)
12/34/56
EX-10.16
from 10-K 3 pages Fulcrum Therapeutics, Inc. Non-Employee Director Compensation Policy Effective January 23, 2026
12/34/56
EX-10.16
from 10-K 3 pages Fulcrum Therapeutics, Inc. Non-Employee Director Compensation Policy Effective January 24, 2025
12/34/56